Table V.
Efficacy outcomes in patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin 1.1 mg/m2 plus PLD 30 mg/m2 3-hour q3wk infusion.
| First author (year) | Type of study | No. | Number of previous lines (median, range) | Platinum-sensitive, n (%) | cycles, median (range) | ORR (%) | Median PFS (months) | Median OS (months) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFla |
|||||||||||
| >6 | 6-12 | >6 | 6-12 | >6 | 6-12 | ||||||
| Monk (2010, 2012) (9, 10) | Phase III clinical trial, randomized Independent review | 337 | 1b | 278 (64.7%) | 6 (1-21) | 35.3% | NA | 9.2 | 7.4 | 27.0 | NA |
| Current study | Single-center retrospective analysis | 34 | 3 (2-10) | 34 (100.0%) | 5 (1-16) | 32.4% | 40.9% | 6.1 | 6.8 | 16.3c | 20.8c |
ORR = objective response rate; OS = overall survival; PFI = platinum-free interval; PFS = progression-free survival; PLD = pegylated liposomal doxorubicin; q3wk = every 3 weeks.
a
Platinum-sensitive disease (PFI >6 months) and partially platinum-sensitive disease (PFI 6-12 months).
b
No data on pretreatment were available, but the inclusion criteria of this study allowed only 1 previous line of treatment.
c
The majority of patients were alive at the time of this retrospective analysis (58% of patients censored) and therefore OS data were very immature.